Stock GLSI GREENWICH LIFESCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
13.19 USD -1.57% Intraday chart for Greenwich LifeSciences, Inc. -2.58% +25.38%
May. 20 Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
AQ
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
AQ
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
AQ
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
AQ
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
AQ
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
AQ
GREENWICH LIFESCIENCES, INC. : Other Events (form 8-K)
AQ
GREENWICH LIFESCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
GREENWICH LIFESCIENCES, INC. : Other Events (form 8-K)
AQ
Greenwich LifeSciences Provides Year End Update
BU
GREENWICH LIFESCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
BU
GREENWICH LIFESCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
GREENWICH LIFESCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
BU
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
BU
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
BU
GREENWICH LIFESCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Greenwich LifeSciences : Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Form 8-K
PU
GREENWICH LIFESCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLSI Stock
  4. News Greenwich LifeSciences, Inc.
  5. Press Releases